ArticleRenal failure2025
The association of plasma TMAO and body composition with the occurrence of PEW in maintenance hemodialysis patients.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TMAO and Cardiovascular Disease: Exploring Its Potential as a Biomarker.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aims to explore the relationship between trimethylamine N-oxide (TMAO), body composition, and protein-energy wasting (PEW) in patients undergoing maintenance hemodialysis (MHD).
methodsA total of 127 MHD patients participated in this study. Body composition was measured using the InBody770 multi-frequency body composition analyzer. Plasma TMAO concentrations were assessed by ELISA. Cross-sectional analysis was performed after collecting demographic data, dialysis-related data, laboratory parameters, and body composition data from MHD patients.
resultsIn MHD patients, the PEW group exhibited lower levels of hemoglobin (Hb), albumin (ALB), transferrin (TF), creatinine (Cr), triglycerides (TG), prealbumin (PALB), soft lean mass (SLM), body mass index (BMI), percent of body fat (PBF), arm muscle circumference (AMC), and phase angle (PHA) compared to the non-PEW group, while C-reactive protein (CRP) and trimethylamine-N-oxide (TMAO) levels, as well as Extracellular Water/Total Body Water (ECW/TBW) ratio, were higher in the PEW group than in the non-PEW group. After full adjustment, TMAO and ECW/TBW ratio were independent risk factors for PEW in MHD patients. Further, plasma TMAO levels correlated negatively with Cr, ALB, Hb, BMI, and PHA, and positively with ECW/TBW in MHD patients with PEW. The ROC curve analysis indicated that the area under the curve (AUC) for plasma TMAO in predicting PEW in MHD patients was 0.788.
conclusionsPlasma TMAO levels and certain body composition are associated with the occurrence of PEW in MHD patients. Plasma TMAO levels appear to serve as a potential predictive marker for the onset of PEW.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.